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A B S T R A C T
Coronavirus disease-2019 (COVID-19) is associated with severe inflammation in mainly the lung, and kidney.
Reports suggest a beneficial effect of the use of heparin/low molecular weight heparin (LMWH) on mortality
in COVID-19. In part, this beneficial effect could be explained by the anticoagulant properties of heparin/
LMWH. Here, we summarise potential beneficial, non-anticoagulant mechanisms underlying treatment of
COVID-19 patients with heparin/LMWH, which include: (i) Inhibition of heparanase activity, responsible for
endothelial leakage; (ii) Neutralisation of chemokines, and cytokines; (iii) Interference with leukocyte traf-
ficking; (iv) Reducing viral cellular entry, and (v) Neutralisation of extracellular cytotoxic histones. Consider-
ing the multiple inflammatory and pathogenic mechanisms targeted by heparin/LMWH, it is warranted to
conduct clinical studies that evaluate therapeutic doses of heparin/LMWH in COVID-19 patients. In addition,
identification of specific heparin-derived sequences that are functional in targeting non-anticoagulant mech-
anisms may have even higher therapeutic potential for COVID-19 patients, and patients suffering from other
inflammatory diseases.









Coronavirus disease-2019 (COVID-19) is caused by the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2
is closely related to other coronaviruses that emerged in the last two
decades including the severe acute respiratory syndrome coronavirus
(SARS-CoV), and the Middle East respiratory syndrome coronavirus
(MERS-CoV). Compared to SARS-CoV, and MERS-CoV, SARS-CoV-2
appears to spread more efficiently within the human population and
officially caused a pandemic by mid-March 2020 [1].
COVID-19 primarily presents with common flu symptoms such as
fever, muscle pain, and cough, and in severe cases causes acute respi-
ratory distress syndrome (ARDS) [2]. Besides ARDS, severely ill
COVID-19 patients may progress to multi-organ dysfunction. Another
common complication of COVID-19 is acute kidney injury (AKI), and
proteinuria, which is leakage of protein into the urine. It is reported
that around 40% of COVID-19 patients developed proteinuria upon
hospital admission [3]. Moreover, in the intensive care unit (ICU) set-
ting 90% of patients presented with AKI [3]. Thus AKI is considered a
negative prognostic factor regarding survival of COVID-19 patients
[4]. Similar to pulmonary oedema, which causes ARDS, proteinuria is
caused by a compromised endothelial glycocalyx, which is normally
comprised of a thick layer of negatively charged glycosaminoglycans
(GAGs). The integrity of the endothelial glycocalyx is crucial for endo-
thelial barrier function, especially in the lungs [5,6], and in the kid-
neys [7,8], and this endothelial barrier seems to be disrupted in
COVID-19 patients. Finally, autopsies from COVID-19 patients identi-
fied the presence of thrombus formation in the microvasculature,
which suggests that coagulation is an important contributor in organ
failure of COVID-19 patients [9,10].
There are no COVID-19-specific treatments or vaccines available,
and care is primarily supportive. The broad spectrum antiviral,
Remdesivir, shows promise by inhibiting viral replication of SARS-
CoV-2 in animal models and shortening the time for clinical improve-
ment [11], as well as the corticosteroid dexamethasone, which
showed a reduction in 28-day mortality in patients requiring oxygen
therapy, or mechanical ventilation upon administration, as described
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in a recent preliminary report [12]. As cohort studies suggest a high
rate of thromboembolic complications among hospitalised patients
[13], prophylactic administration with LMWH for hospitalised
COVID-19 patients is recommended [14], whereas some experts rec-
ommend higher doses for critically ill patients. LMWH is preferred
over unfractionated heparin due to the decreased risk of bleeding,
good predictability, dose-dependent plasma levels and longer half-
life [15,16]. Data from retrospective studies suggest that the use of
heparin/LMWH may improve outcome in COVID-19, although evi-
dence of prospective trials is needed before more firm conclusions
can be drawn [1719]. Systemic anticoagulation was associated with
improved in-hospital survival among hospitalized patients with
COVID-19, but only in the subgroup of intubated patients [19]. Nota-
bly, a retrospective study from China found systemic anticoagulation
mainly with LMWH to be associated with a lower mortality, however
only 15% of patients in this cohort were using LMWH and the survival
benefit was restricted to those with a high sepsis-induced anticoagu-
lant score, or D-dimer level [17]. In addition to functioning as anticoa-
gulants, heparins have other therapeutic functions that are relevant
for the treatment of COVID-19-associated clinical manifestations, i.e.
neutralisation of inflammatory chemokines, and cytokines, such as
CXCL-1, IL-6, and IL-8 that play a key role in ARDS; neutralisation of
extracellular cytotoxic histones and by interfering with leukocyte
trafficking [20]. Since the biological roles of heparins are versatile, it
is currently debated via which mechanisms heparin/LMWH could be
beneficial for COVID-19 patients (Fig. 1) [20].
One important, currently overlooked characteristic of heparin/
LMWH in the pathogenesis of COVID-19 is the inhibitory effect on
heparanase (HPSE) [21]. HPSE mediates the disruption of the endo-
thelial barrier, in particular by degrading the endothelial glycocalyx,
which has also been described for several pathologies such as pulmo-
nary oedema, and proteinuric kidney disease [5,7,8,2225]. This sug-
gests that increased HPSE activity may play a role in the severe
clinical manifestations of COVID-19, including ARDS, and AKI. Nota-
bly, in a recent preprint we showed increased plasma HPSE activity
in COVID-19 patients [26].
The aim of this review is to summarise the literature concerning
the non-anticoagulant functions of heparin/LMWH with a special
focus on: the inhibition of HPSE activity, neutralisation of chemo-
kines/cytokines, inhibition of leukocyte trafficking, and neutralisation
of extracellular cytotoxic histones in the circulation. We propose that
therapeutic treatment with heparin/LMWH will interfere with sev-
eral pathological processes in COVID-19 patients, thereby increasing
their survival rate.
2. Potential beneficial non-anticoagulant effects of heparin/
LMWH treatment for COVID-19 patients
2.1. Heparin/LMWH inhibits HPSE activity
As outlined, leakage of proteins, and fluid across the endothelial bar-
rier is manifested in most severe clinical outcomes of COVID-19, includ-
ing ARDS, and proteinuria. In normal physiological conditions, the
endothelial glycocalyx prevents leakage of proteins in a charge and
size-dependent manner [8]. Heparan sulphate (HS) is the most abun-
dant sulphated GAG in the glycocalyx and is the main contributor to its
negative charge-dependent barrier function [8,22]. HPSE is the only
known mammalian enzyme capable of degrading HS. Hence, prolonged,
increased activity of HPSE compromises the glycocalyx, which causes a
subsequent loss of endothelial barrier function and leaky blood vessels
that contribute to lung and kidney complications, as observed in ARDS
and proteinuric kidney diseases [5,7,8,2225]. HPSE also plays a pre-
dominant role in systemic vascular leakage induced by sepsis [25,27],
or severe dengue disease [28]. Attenuation of HPSE activity in models of
aforementioned diseases prevented endothelial hyperpermeability, and
protein leakage [25,2730], thereby protecting from severe injury and
preserving lung, and kidney function [25,31]. Therefore, the loss of
endothelial barrier function in COVID-19, leading to pulmonary oedema,
and proteinuria, may be in part the result of increased HPSE-mediated
degradation of the glycocalyx. Consequently, inhibition of HPSE activity
may benefit COVID-19 patients with complications caused by a leaky
vasculature, i.e. ARDS, proteinuria, by preventing glycocalyx dysfunc-
tion. Importantly, heparin/LMWH, and chemical heparin derivatives
have proven to be potent HPSE inhibitors [21,3234]. In line with this,
in a recent preprint we showed that non-ICU patients receiving the
LMWH dalteparin in a prophylactic dose of 5000 IU daily had a signifi-
cantly lower HPSE activity, suggesting that clinically relevant inhibition
of HPSE activity can already be reached using prophylactic-dose LMWH
[26]. Taken together, we hypothesise that inhibition of increased HPSE
activity by heparin/LMWH could be one of the main mechanisms to
reduce severe clinical manifestations of COVID-19.
2.2. Heparin/LMWH has anti-inflammatory properties
Heparin/LMWH possesses multiple anti-inflammatory properties
and various mechanisms underlying the anti-inflammatory effect of
heparin/LMWH have been proposed [16,35,36]. The potential of hep-
arin/LMWH as a therapeutic compound for inflammatory diseases
has been supported by clinical trials [36], experimental models in
bronchial asthma, ulcerative colitis, burns, ischemia-reperfusion,
arthritis, and peritonitis [35,37]. In addition to its contribution to
endothelial barrier function, the endothelial glycocalyx also mediates
several inflammatory processes. The specific sulphation patterns of
GAGs observed in a healthy endothelial glycocalyx attenuates bind-
ing of chemokines and leukocytes to the endothelial cell surface [38].
However, the structure of GAGs changes under inflammatory condi-
tions, which facilitates the binding of chemokines, as well as selec-
tins, and integrins expressed by leukocytes [5,39]. Increased HPSE
activity is also involved in the development of a proinflammatory
glycocalyx. Cells exposed to HPSE show an enhanced response to
stimuli, such as proinflammatory cytokines [40,41]. Furthermore, HS
fragments shed by HPSE contribute to the inflammatory extracellular
milieu, for example, by the release of sequestered chemokines, and/
or the binding of HS fragments to toll-like receptors [42,43]. Impor-
tantly, HPSE deficiency and/or HPSE inhibition supports beneficial
outcomes in experimental inflammatory lung and kidney disease,
which may be also relevant for the clinical complications of COVID-
19 [22,25,31,44,45].
COVID-19 is associated with production of high levels of pro-
inflammatory cytokines [46]. Heparin/LMWH are able to bind to the
vast majority of chemokines and cytokines including IL-8 [47,48].
Heparin/LMWH binding of chemokines/cytokines may neutralise
their biological effect. Under inflammatory conditions, chemokine
and cytokine binding to endothelial cell surface GAGs promotes acti-
vation and trafficking of leukocytes, i.e. endothelial cell-bound IL-8
mediates chemotaxis of neutrophils. However, exogenous heparin
and LMWH disrupts this process by competing with endothelial cell
surface HS for IL-8 [47,48]. Besides neutralisation of chemokine and
cytokine function, both heparin and LMWH has also been shown to
inhibit cytokine synthesis including TNF-a, IFN-g , IL-6, and IL-8 via
inhibition of NF-kB signalling [16,49]. In addition, LMWH may also
interfere with the bradykinin pathway, which has been proposed in a
recent preprint to be over-activated in COVID-19 due to the con-
sumption of angiotensin converting enzyme-2 during viral entry
[50]. Endothelial cell surface GAGs regulate activation of bradykinin
pathways and HS degradation by HPSE promotes proteolytic bradyki-
nin generation from high molecular weight kininogen [51]. There-
fore, LMWH may inhibit bradykinin formation both via inhibition of
HPSE activity and by its ability to bind high molecular weight kinino-
gen, thereby attenuating the local inflammation and vascular leakage
in COVID-19 [52].
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COVID-19 is also associated with the influx of immune cells
[53,54]. Notably, leukocyte rolling, firm adhesion to endothelial cells,
and transmigration can be attenuated by heparin/LMWH [55,56].
Several studies demonstrated that heparin/LMWH interferes with
leukocyte rolling, adhesion, and migration, via binding to L-selectin,
P-selectin, and Mac-1/CD11b expressed by leukocytes, consequently
competing with the interaction of endogenous binding sites present
in endothelial cell surface GAGs [57,58]. Since leukocyte activation
and trafficking play a central role in the inflammatory response of
COVID-19 [53,54], inhibition of leukocyte adhesion and migration by
heparin/LMWH could dampen the immune response.
Finally, heparin/LMWH inhibits complement activation [16,59].
The complement system plays an important role in innate immune
defence and shaping of adaptive immune responses. Activation of the
Fig. 1. Summary of the potential beneficial mechanisms of heparin/low molecular weight heparin (LMWH) underlying treatment of COVID-19 patients. 1. Reducing viral entry. Hep-
aran sulphate, and heparin/LMWH have been shown to interact with SARS-CoV-2 spike glycoprotein. 2. Inhibition of heparanase activity. Heparin/LMWH has been shown to inhibit
heparanase activity, which is increased in COVID-19 and associated with disease severity. 3. Neutralisation of the biological effect of chemokines, and cytokines. Heparin/LMWH
interact with chemokines, and cytokines, including those produced in the ‘cytokine storm’ in COVID-19. 4. Interference with leukocyte trafficking. Heparin/LMWH neutralisation of
chemokine, and cytokines may impact on leukocyte recruitment and trafficking to sites of inflammation, either via neutralisation of chemokine, and cytokines or through direct
interaction with leukocyte cell surface ligands, i.e. selectins, and integrins, to prevent leukocyte attachment, and extravasation. 5. Anticoagulation. Heparin/LMWH promotes antico-
agulation via anti-thrombin III binding. 6. Neutralisation of extracellular cytotoxic histones. Heparin/LMWH act as a neutralising compound for histones via ionic interactions of the
negatively charged chemical groups with the positively charged extracellular histones released during COVID-19.
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complement system leads to many processes such as opsonisation
and phagocytosis of pathogens, chemotaxis of neutrophils, and
release of inflammatory mediators. Excessive complement activation
has been proposed to contribute to systemic thrombosis in COVID-19
patients [60,61]. Complement inhibition in SARS-CoV [62], and
MERS-CoV [63] murine models was associated with favourable out-
comes, suggesting that the same may be true for COVID-19. Heparin/
LMWH interferes with complement activation at multiple levels,
including binding to C1q and inhibiting the cleavage of C2, C3, and C4
[16]. Heparin/LMWH therefore inhibits activation of all three of the
complement pathways at various points.
In summary, the most severe complications of COVID-19 involve
inflammation, including neutrophil infiltration [53], of the lung, and
kidney. The anti-inflammatory properties of heparin/LMWH may
therefore facilitate dampening of the inflammatory response via mul-
tiple mechanisms.
2.3. Heparin/LMWH reduces viral entry to host cells
Many viruses (including some coronaviruses) utilise cellular HS as
co-receptors for cell attachment [64,65], enabling a localised increase
in viral particle concentration to maximise infection rates [66]. Simi-
larly, a novel GAG-binding motif was identified within the SARS-
CoV-2 spike glycoprotein (SGP), the viral fusion protein responsible
for receptor binding and fusion of the viral and host membranes,
which is not present in the SGPs of SARS-CoV, or MERS-CoV [67].
Moreover, it was shown in a preprint that SARS-CoV-2 SGP binds
more tightly to immobilised heparin than the SARS-CoV, and MERS-
CoV SGPs [68]. Recent preprints by using competitive binding
approach showed that both soluble heparin, highly sulphated HS and
heparin-derived tetrasaccharides inhibited binding of SARS-CoV-2 to
immobilised heparin [6870]. SARS-CoV-2 entry into Vero cells
in vitro was also competitively inhibited by heparin [71], illustrating
a functional role of this newly identified SARS-CoV-2 SGP GAG-bind-
ing motif for viral host infection. Using a high titre lentivirus pseudo-
typed with SARS-CoV-2 SGP, a separate study then showed that
unfractionated heparin (IC50, 599 ng/L) and LMWH (enoxaparin, IC50,
108 mg/L) both effectively inhibited infection of HEK293T cells [66].
This potency in inhibition of SARS-CoV-2 SGP/GAG binding mecha-
nism suggests that heparin/LMWH may have immediate therapeutic
potential by preventing SARS-CoV-2 infection, thereby attenuating
disease severity in COVID-19 patients.
2.4. Heparin/LMWH neutralises circulating histones
SARS-CoV-2 has been suggested to induce different forms of cell
death including apoptosis [72], and neutrophil extracellular trap
(NET) formation [53,73]. Excessive endothelial cell death could
directly cause disruption of the endothelial barrier leading to vascular
leakage of proteins and fluid. Notably, NETs have been shown to
induce endothelial-to-mesenchymal transformation in vitro and pro-
tein leakage across endothelial monolayers [74,75]. In particular,
NOX-independent NETs activated endothelial cells, which was
accompanied by diminished barrier function [76].
Histones are highly conserved positively charged proteins, which
are essential for chromatin structure and regulation of gene expres-
sion. However, when present in the extracellular space upon cell
death, histones induce an inflammatory response and are highly
cytotoxic contributing to necrosis, apoptosis and the formation of
NETs [77,78]. Recent studies have reported that NETs are present in
tissues and the circulation of COVID-19 patients [75], suggesting that
their cytotoxicity contributes to disease. Negatively charged heparin
and, desulphated heparin oligosaccharides has been demonstrated to
neutralise the cytotoxic effect of positively charged histones, thereby
potentially reducing organ damage [7981]. In summary, heparin/
LMWH may neutralise the inflammatory and cytotoxic effects of
extracellular histones in COVID-19.
3. Conclusions, outstanding questions and future perspectives
Due to the multiple inflammatory and pathogenic mechanisms
targeted by heparin/LMWH, it is warranted to conduct clinical studies
that evaluate therapeutic doses of these compounds in COVID-19
patients. Although a prophylactic dose of LMWH is associated with a
reduced HPSE activity in non-ICU COVID-19 patients [26], regarding
the other possible non-anticoagulant effects, no data is currently
available as to whether heparin/LMWH in their usual prophylactic, or
therapeutic dosage are effective to prevent viral entry, to neutralize
cytokines and histones, and to interfere with leukocyte trafficking. In
fact, the optimal anticoagulant dosing in patients with COVID-19 is
currently uncertain. Studies suggest a high rate of thromboembolic
complications among hospitalized patients with COVID-19, particu-
larly in patients admitted to the ICU, and often despite prophylactic-
dose anticoagulation [13]. This has led some experts to recommend a
higher-intensity thromboprophylaxis with intermediate or even
therapeutic dosages of LMWH in critically ill patients with COVID-19
[13]. The balance between the risks of thrombosis, and the possible
beneficial non-coagulant effects of higher LMWH dosing on the one
hand, and the risks of bleeding on the other hand await further study.
Considering the structural diversity of heparin/LMWH, in the long
term well-defined, heparin-derived structures should be identified
that interfere with SARS-CoV-2 cellular entry, COVID-19 related
HPSE activity, chemokine binding, leukocyte trafficking, and histone
neutralisation, in analogy to the heparin-based pentasaccharide
(Arixtra/Fondaparinux) that mediates anticoagulation via antithrom-
bin III. A mixture of these well-defined, heparin-derived compounds
could be beneficial for the outcome of COVID-19 patients, as well as
for patients suffering from other inflammatory diseases.
4. Search strategy and selection criteria
Data for this review were identified by searches of PubMed, and
preprint servers, and references from relevant articles using the
search terms “COVID-19”, “Heparin”, “Non-anticoagulant functions of
heparin”, “Low molecular weight heparin”, “ARDS”, “Kidney dysfunc-
tion”, “Endothelial barrier dysfunction”, “Heparanase”, “Heparan sul-
phate”, “Viral entry”, ”Heparanase inhibition”, “Inflammation”,
“Complement system”, and “Neutrophil extracellular traps”.
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